MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma

Epidermal growth factor receptor (EGFR) targeted therapies have shown limited efficacy in head and neck squamous cell carcinoma (HNSCC) patients despite its overexpression. Identifying molecular mechanisms associated with acquired resistance to EGFR-TKIs such as erlotinib remains an unmet need and a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Jain, Ankit P., Patel, Krishna, Pinto, Sneha, Radhakrishnan, Aneesha, Nanjappa, Vishalakshi, Kumar, Manish, Raja, Remya, Patil, Arun H., Kumari, Anjali, Manoharan, Malini, Karunakaran, Coral, Murugan, Saktivel, Keshava Prasad, T. S., Chang, Xiaofei, Mathur, Premendu Prakash, Kumar, Prashant, Gupta, Ravi, Gupta, Rohit, Khanna-Gupta, Arati, Sidransky, David, Chatterjee, Aditi, Gowda, Harsha
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6906491/
https://ncbi.nlm.nih.gov/pubmed/31827134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55208-5
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares